Connect your AI

Johnson & Johnson JNJ Stock-Based Comp

Stock-Based Comp at other companies

AbbottABT

$317M+9.7%

Bristol-Myers SquibbBMY

$146M+1.4%

Tenet HealthcareTHC

$25M+19.0%

PfizerPFE

$272M+60.0%

Procter & GamblePG

$132M+7.3%

Merck & Co.MRK

$185M-5.1%

Other financials

Income statement

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

Market cap$613.02B+67.4%

Enterprise value$646.32B+62.2%

P/E29.1×+13.0×

P/S6.4×+2.3×

Profitability

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Johnson & Johnson's stock-based comp?: Johnson & Johnson (JNJ) reported stock-based comp of $300M in Q1 2026.
How has Johnson & Johnson's stock-based comp changed year-over-year?: Johnson & Johnson's stock-based comp increased by 4.2% year-over-year, from $288M to $300M.
What is the long-term trend for Johnson & Johnson's stock-based comp?: Over 4 years (2021 to 2025), Johnson & Johnson's stock-based comp has grown at a 4.5% compound annual growth rate (CAGR), from $1.14B to $1.35B.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.